Nu-Med Plus, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q2 2026.

Public ticker
NUMD on OTC
Latest financial report
14 Aug 2026
Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Port Jefferson, NY
SEC filing record 1 source field available
Fiscal year end
31 December

Shareable Research Card

NUMD - Nu-Med Plus, Inc. Financial Facts

NUMD - Nu-Med Plus, Inc. has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.

Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.

Context
Latest metrics period: Q2 2026
Latest reported value
Return On Invested Capital 8.4%

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.

Open stable link Open latest 10-Q/10-K hub

Return Loop

Why revisit this company facts page

Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.

Latest source-backed update
Latest metrics period Q2 2026
Why come back
Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
  • Current latest metrics period: Q2 2026.
  • Most recent SEC facts end date on this page: 14 Aug 2026.
  • Save this filer to return when the next filing-backed metric period changes the picture.

Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.

Create account to save this filer Open latest 10-Q/10-K hub

Latest update

Latest update for NUMD - Nu-Med Plus, Inc.

New fact period available

Latest financial period: Q2 2026. Reopen this facts page to verify the newest reported period against the prior baseline.

Update date

14 Aug 2026

Page type

Company facts

Latest period

Q2 2026

SEC-backed company facts were refreshed from filings filed on 14 Aug 2026.

Open recent updates hub Open latest 10-Q/10-K hub

Benchmark Context

How Return On Invested Capital compares

Return On Invested Capital does not yet have enough prior-period data for a historical comparison on this page.

Compared with

Compared with Nu-Med Plus, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.

Why this is notable

Return On Invested Capital already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.

  • Latest comparable period on this page: Q2 2026.
  • Peer context will appear when enough companies report a comparable value for this metric.
  • Open the metric history first if you want to verify the exact period-to-period change.

Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.

Open latest 10-Q/10-K hub

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it

Key facts

  • NUMD - Nu-Med Plus, Inc. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q2 2026.
  • Headline metric: Return On Invested Capital 8.4%.

Change

  • Return On Invested Capital YoY change: .
  • Most recent SEC facts end date: 14 Aug 2026.

Research use

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Evidence

Based on latest 10-Q/10-K

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.

View source filing

Latest SEC snapshot (2026-08-14) highlights Return On Invested Capital 8.4%, Return On Equity -7.7%, and Return On Assets 152.4%.

Valuation Snapshot

SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.

No market comparison No market comparison Low confidence

Fair value per share

$0.2198

Market price

n/a

NUMD

PEG ratio

n/a

Enterprise value

$18.27M

Equity value

$18.36M

DCF fair value scenarios

Bear

$0.1643

No market comparison
Growth
1%
Discount
11%
Terminal
2%

Base

$0.2198

No market comparison
Growth
4%
Discount
10%
Terminal
2.5%

Bull

$0.3071

No market comparison
Growth
7%
Discount
9%
Terminal
3%

Base growth: DCF Growth Assumption.

Key valuation metrics

EV/Revenue

n/a

Market price market EV / SEC revenue

Market enterprise value is unavailable

EV/EBITDA

n/a

Market price market EV / SEC EBITDA

Market enterprise value is unavailable

P/E

n/a

Market price market price / SEC EPS

Market cap is unavailable

P/S

n/a

Market price market cap / SEC revenue

Market cap is unavailable

P/B

n/a

Market price market cap / SEC equity

Market cap is unavailable

PEG

n/a

P/E / DCF Growth Assumption

P/e or positive growth is unavailable

Core assumptions

Projection
5 years
FCF growth
4%
Discount rate
10%
Terminal growth
2.5%

SEC fact inputs

DCF base FCF
$1.25M
Trailing SEC FCF
Reported FCF
$1.25M
Net income
$19.7K
EBITDA
$22.6K
Cash
$5.4K
Debt
$100K
Equity
$267.5K
Shares
83,548,469

Data confidence notes

  • Dcf base free cash flow: dcf base starts from trailing sec free cash flow
  • Dcf base free cash flow: trailing free cash flow is not positive
  • Dcf confidence is low for this sec-only free cash flow estimate
  • Market price unavailable
  • Base free cash flow is negative; dcf output is mechanically computed but high risk
  • Peg unavailable: market price is missing

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

37.5/100

Weak Confidence medium

Return On Invested Capital

8.4%

Metric score 22.9/100

Return On Equity

-7.7%

Metric score 0.0/100

Return On Assets

152%

Metric score 100.0/100

Financial Health

Current Ratio
0.05x
Debt to Equity
-0x

Strengths

Return On Assets and Debt-to-equity

Watchpoints

Return On Invested Capital, Return On Equity, and Current Ratio

Key metrics snapshot

Profitability

Metric Latest value YoY change
Return On Invested Capital 8.4%
Return On Equity -7.7% -127%
Return On Assets 152%

Financial Health

Metric Latest value YoY change
Current Ratio 0.05x
Debt-to-equity -0x

Growth

Metric Latest value YoY change
Revenues $0
Net Income (Loss) Attributable to Parent $19,670

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 83,548,469
Common Stock, Shares, Outstanding 83,548,469
Common Stock, Value, Issued $83,549
Weighted Average Number of Shares Outstanding, Basic 83,548,469 0%
Weighted Average Number of Shares Outstanding, Diluted 83,548,469 0%

Supporting Metrics

These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.

Metric Latest value YoY change
Accounts Payable, Current $33,909
Accrued Liabilities, Current $23,509
Additional Paid in Capital $9,594,687
Assets $12,909
Assets, Current $12,909
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5,409 +527%
Common Stock, Par or Stated Value Per Share 0.001
Common Stock, Shares Authorized 90,000,000
Common Stock, Shares, Issued 83,548,469
Earnings Per Share, Basic 0
Earnings Per Share, Diluted 0
General and Administrative Expense $8,073 +48%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $19,670
Income Tax Expense (Benefit) $0
Liabilities $280,395
Liabilities and Equity $12,909
Liabilities, Current $280,395
Nonoperating Income (Expense) $42,226
Operating Income (Loss) $22,556 -116%
Preferred Stock, Par or Stated Value Per Share 0.001
Preferred Stock, Shares Authorized 10,000,000
Preferred Stock, Shares Issued 0
Preferred Stock, Shares Outstanding 0
Property, Plant and Equipment, Net $0
Retained Earnings (Accumulated Deficit) $9,945,722
Stockholders' Equity Attributable to Parent $267,486 -8.4%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .